Jennifer A. Wellman
Direttore operativo presso AKOUOS
Profilo
Jennifer A.
Wellman is the founder of Spark Therapeutics, Inc., which was founded in 2013.
She held the title of Head-Product Development & Regulatory Strategy at Spark Therapeutics, Inc. Ms. Wellman is currently an Independent Director at Atsena Therapeutics, Inc. since 2021 and Chief Operating Officer at Akouos, Inc. since 2020.
In the past, she worked as a Regulatory Director at Raymond G.
Perelman Center for Cellular & Molecular from 2005 to 2013 and as an Associate Scientist at Avigen, Inc. from 2000 to 2005.
Ms. Wellman completed her undergraduate degree at Queen's University and her graduate degree at the University of New Haven.
Posizioni attive di Jennifer A. Wellman
| Società | Posizione | Inizio |
|---|---|---|
| AKOUOS | Direttore operativo | 01/10/2020 |
Atsena Therapeutics, Inc.
 Atsena Therapeutics, Inc. BiotechnologyHealth Technology Atsena Therapeutics, Inc. engages in biotechnology business. The company is headquartered in Durham, NC. | Direttore/Membro del Consiglio | 12/07/2021 |
Precedenti posizioni note di Jennifer A. Wellman
| Società | Posizione | Fine |
|---|---|---|
| Raymond G. Perelman Center for Cellular & Molecular | Consigliere Generale | 01/01/2013 |
Avigen, Inc.
 Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | Corporate Officer/Principal | 01/01/2005 |
| SPARK THERAPEUTICS, INC. | Fondatore | - |
Formazione di Jennifer A. Wellman
| Queen's University | Undergraduate Degree |
| University of New Haven | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Avigen, Inc.
Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | Health Technology |
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Akouos, Inc.
 Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. | Health Technology |
Atsena Therapeutics, Inc.
Atsena Therapeutics, Inc. BiotechnologyHealth Technology Atsena Therapeutics, Inc. engages in biotechnology business. The company is headquartered in Durham, NC. | Health Technology |
| Raymond G. Perelman Center for Cellular & Molecular |
- Borsa valori
- Insiders
- Jennifer A. Wellman
